Anna Bunin

Company: Biohaven Pharmaceuticals

Job title: Director, Discovery and Translational Biology

Seminars:

Targeting circulating IgG for the Treatment of Autoimmune Disease 12:00 pm

Introducing the concept of extracellular protein degradation and highlighting its idiosyncrasy and potential advantages over other approaches with the focus on Biohaven Pharmaceuticals’ ASGPR based degradation. Uncovering IgG degradation in discovery and preclinical studies – progression of a development candidate towards IND Considering what else can be done; Targets, indications, applicationsRead more

day: Post-Conference Focus Day: Next Generation TPD